COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS TREATMENT IN SPAIN

被引：0
|
作者：
Vazquez, M. [1 ]
Canete, J. D. [2 ]
Nicolas, J. [3 ]
Peral, C. [4 ]
Gomez, S. [4 ]
Lopez, A. [4 ]
Prades, M. [5 ]
Rebollo, F. [4 ]
机构：
[1] Hosp Ramon & Cajal, Rheumatol Dept, Madrid, Spain
[2] Hosp Clin Barcelona, Rheumatol Dept, Barcelona, Spain
[3] Hosital Univ Mutua Terrassa, Pharm Dept, Terrassa, Spain
[4] Pfizer SLU, Madrid, Spain
[5] Outcomes10, Castellon De La Plana, Spain
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY16
引用
收藏
页码：S904 / S904
页数：1
相关论文
共 50 条
  • [21] Effects of Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Response to Periodontal Treatment in Patients with Rheumatoid Arthritis
    Jung, Gyu-Un
    Han, Ji-Young
    Hwang, Kyung-Gyun
    Park, Chang-Joo
    Stathopoulou, Panagiota G.
    Fiorellini, Joseph P.
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [22] Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
    Charles-Schoeman, Christina
    Burmester, Gerd
    Nash, Peter
    Zerbini, Cristiano A. F.
    Soma, Koshika
    Kwok, Kenneth
    Hendrikx, Thijs
    Bananis, Eustratios
    Fleischmann, Roy
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (07) : 1293 - 1301
  • [23] ANNUAL TREATMENT COST OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Hosseini, R.
    Brown, L. M.
    Fleming, M.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2024, 27 (06) : S110 - S110
  • [24] TOFACITINIB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE ACTIVE PSORIATIC ARTHRITIS INTOLERANT OR WITH THERAPEUTIC FAILURE TO SYNTHETIC OR BIOLOGICAL DISEASE-MODIFYING DRUGS
    Costa, M.
    Santos, M.
    VALUE IN HEALTH, 2020, 23 : S599 - S599
  • [25] Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents A Cost-Effectiveness Analysis
    Finckh, Axel
    Bansback, Nick
    Marra, Carlo A.
    Anis, Aslam H.
    Michaud, Kaleb
    Lubin, Stanley
    White, Marc
    Sizto, Sonia
    Liang, Matthew H.
    ANNALS OF INTERNAL MEDICINE, 2009, 151 (09) : 612 - W198
  • [26] Cost-Effectiveness of Biologic Response Modifiers Compared to Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: A Systematic Review
    van der Velde, Gabrielle
    Pham, Ba'
    Machado, Marcio
    Ieraci, Luciano
    Witteman, William
    Bombardier, Claire
    Krahn, Murray
    ARTHRITIS CARE & RESEARCH, 2011, 63 (01) : 65 - 78
  • [27] Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial
    Kremer, Joel
    Li, Zhan-Guo
    Hall, Stephen
    Fleischmann, Roy
    Genovese, Mark
    Martin-Mola, Emilio
    Isaacs, John D.
    Gruben, David
    Wallenstein, Gene
    Krishnaswami, Sriram
    Zwillich, Samuel H.
    Koncz, Tamas
    Riese, Richard
    Bradley, John
    ANNALS OF INTERNAL MEDICINE, 2013, 159 (04) : 253 - +
  • [28] Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control
    Lillegraven, Siri
    Sundlisaeter, Nina Paulshus
    Aga, Anna-Birgitte
    Sexton, Joseph
    Solomon, Daniel H.
    van der Heijde, Desiree
    Haavardsholm, Espen A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (12): : 1024 - 1026
  • [29] Combinations of conventional disease-modifying antirheumatic drugs
    O'Dell, JR
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2001, 27 (02) : 415 - 426
  • [30] ASSESSING TREATMENT PATTERNS WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND PREDNISONE FOR PSORIATIC ARTHRITIS BY RACE/ETHNICITY
    Ahmed, F.
    Ogdie, A.
    Fitzsimmons, R.
    Shin, D.
    Takeshita, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 843 - 843
12345